The Pharmaceutical Market: Hungary

Date: January 31, 2013
Pages: 95
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P536428B416EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Hungary
OVERVIEW OF THE PHARMACEUTICAL MARKET IN HUNGARY

Our outlookforHungary's pharmaceutical market remains negative, given thegovernment's policies that shift the burden of the National Healthcare Fund (OEP) onto drug manufacturers. Pricing pressure and claw-back taxes have squeezed domestic manufacturers'margins and introduced insecurity to an already difficulteconomicenvironment, and we continue to expect a contraction in the size of the Hungarian pharmaceutical market in 2012 and 2013. Consequently, Hungariandrugmakers willhave to becomeevenmore export-orientated.That said, afavourable tax regime forresearchanddevelopment shouldattract foreigninvestment, though these multinationals will focus most of their sales effortsonexternal markets, supporting our view that Hungary's status as anet exporter of pharmaceutical productswillincrease.

Headline Expenditure Projections:

Pharmaceuticals: HUF691.61bn (US$3.44bn) in 2011 to HUF608.22bn (US$2.71bn) in 2012;
-12.1% in local currency terms and -21.2% in US dollar terms. Forecast down from Q4 12 due to cost-containment measures .

Healthcare: HUF2,013bn (US$10.01bn) in 2011 to HUF2,003bn (US$8.92bn) in 2012; -0.5% in local currency terms and -10.8% in US dollar terms. Forecast in line with Q4 12 .

Medical Devices: HUF117.09bn (US$582mn) in 2011 to HUF117.95bn (US$526mn) in 2012; +0.7% in local currency terms and -9.7% in US dollar terms. Forecast in line with Q4 12.

Risk/Reward Rating: In our Risk/Rewards Rating (RRR) matrix for Q113, Hungary's composite score again stands at 53.1 out of the maximum 100 points, ranking the country 8th out of 20 markets surveyed in the emerging Europe region. We also retain our pessimistic outlook for its pharmaceutical market rewards, on account of government's cost-containment policies.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Hungary Pharmaceuticals And Healthcare Industry SWOT
    Hungary Political SWOT
    Hungary Economic SWOT
    Hungary Business Environment SWOT

PHARMACEUTICALS RISK/REWARD RATINGS

    Table: Central And Eastern Europe Pharmaceutical Risk/Reward Ratings, Q113
    Rewards

HUNGARY – MARKET SUMMARY

REGULATORY REGIME

    Table: Marketing Authorisation Fees, 2011
    Pharmaceutical Advertising
    Intellectual Property Regime
    Pricing Regime
    Pharmaceutical Mark-ups
    Table: Hungary – Pharmaceutical Price Build-Up (%)
    Reimbursement Regime
    Pricing and Reimbursement Amendments In 2011 and 2012
    Table: Additional Savings Outlined in Szell Kalman 2.0 Plan Incorporating All Public Expenditure

INDUSTRY DEVELOPMENTS

    Epidemiology
    Table: Leading Causes of Death, 2009
    Communicable Disease
    Healthcare System
    Healthcare Funding
    Table: Health Insurance Fund Expenditure by Type, 2004-2009 (HUF mn)
    Public Pharmaceutical Expenditure
    Medical Tourism
    Research and Development
    Clinical Trials
    Medical Devices

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales Indicators, 2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure Indicators, 2008-2016
    Table: Healthcare Governmental Indicators, 2008-2016
    Table: Healthcare Private Indicators, 2008-2016

KEY GROWTH FACTORS – MACROECONOMIC

    Table: Hungary Long-Term Macroeconomic Forecasts
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators, 2008-2016
    Patented Drug Market Forecast
    Hungary Pharmaceuticals & Healthcare Report Q1 2013
    Table: Patented Drug Market Indicators, 2008-2016
    Generic Drug Market Forecast
    Table: Generic Drug Sales Indicators, 2008-2016
    OTC Medicine Market Forecast
    Table: OTC Medicine Sales Indicators, 2008-2016
    Table: OTC Medicine Sales Sub-Indicators, 2005-2010
    Pharmaceutical Trade Forecast
    Table: Exports and Imports Indicators, 2008-2016
    Medical Device Market Forecast
    Table: Medical Devices Sales Indicators, 2008-2016
    Other Healthcare Data Forecasts
    Key Risks to BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

    Pharmaceutical Industry
    Table: Members of MAGYOSZ, 2011
    Table: Members of AIPM, 2011
    Domestic Players
    Table: Hungarian Pharmaceutical Production, 1990-2008 (HUF billions)
    Foreign Players
    Recent Company Activities
    Pharmaceutical Wholesale
    Pharmaceutical Retail
    Table: Pharmacies, 2000-2010

COMPANY MONITOR

    Domestic Manufacturers
    Gedeon Richter
    Egis Pharmaceuticals (Servier)
    Foreign Manufacturers
    Pfizer
    Novartis
    Sanofi
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Teva

COUNTRY SNAPSHOT: HUNGARY DEMOGRAPHIC DATA

    Table: Hungary – Population By Age Group, 1990-2020
    Table: Hungary –Population By Age Group, 1990-2020
    Table: Hungary – Key Population Ratios, 1990-2020
    Table: Hungary - Rural and Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How we Generate our Pharmaceutical Industry Forecasts
    Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Weighting
    Table: Weighting Of Components
Skip to top


The Pharmaceutical Market: Jordan US$ 1,295.00 Jan, 2013 · 112 pages
The Pharmaceutical Market: Malaysia US$ 1,295.00 Jan, 2013 · 113 pages
The Pharmaceutical Market: Mexico US$ 1,295.00 Jan, 2013 · 165 pages

Ask Your Question

The Pharmaceutical Market: Hungary
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: